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Abstract
Background: Persistent stimulation of cardiac β1-adrenergic receptors by endogenous
norepinephrine promotes heart failure progression. Polymorphisms of this gene are known to alter
receptor function or expression, as are polymorphisms of the α2C-adrenergic receptor, which
regulates norepinephrine release from cardiac presynaptic nerves. The purpose of this study was
to investigate possible synergistic effects of polymorphisms of these two intronless genes (ADRB1
and ADRA2C, respectively) on the risk of death/transplant in heart failure patients.
Methods: Sixteen sequence variations in ADRA2C and 17 sequence variations in ADRB1 were
genotyped in a longitudinal study of 655 white heart failure patients. Eleven sequence variations in
each gene were polymorphic in the heart failure cohort. Cox proportional hazards modeling was
used to identify polymorphisms and potential intra- or intergenic interactions that influenced risk
of death or cardiac transplant. A leave-one-out cross-validation method was utilized for internal
validation.
Results: Three polymorphisms in ADRA2C and five polymorphisms in ADRB1 were involved in eight
cross-validated epistatic interactions identifying several two-locus genotype classes with significant
relative risks ranging from 3.02 to 9.23. There was no evidence of intragenic epistasis. Combining
high risk genotype classes across epistatic pairs to take into account linkage disequilibrium, the
relative risk of death or transplant was 3.35 (1.82, 6.18) relative to all other genotype classes.
Conclusion: Multiple polymorphisms act synergistically between the ADRA2C and ADRB1 genes to
increase risk of death or cardiac transplant in heart failure patients.
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Background
Congestive heart failure can be caused by a wide array of
myocardial insults. Although this etiological heterogeneity has yet to be well characterized, the role of neurohormonal pathways in the progression of heart failure is well
established [1-3]. Prejunctional α2-adrenergic receptors
(α2A and α2C) regulate the release of norepinephrine from
cardiac sympathetic nerves in a negative feedback manner.
When these receptors are ablated in mouse models,
uncontrolled norepinephrine release causes a lethal cardiomyopathy [4,5]. Moreover, the released norepinephrine
activates β1-adrenergic receptors (β1AR) expressed on cardiac myocytes which are coupled to stimulatory G-proteins that propagate signals to downstream effectors such
as adenylyl cyclase, ion channels, and phospholipases [6].
Prolonged activation of cardiomyocyte β1AR signaling by
any number of pharmacologic or genetic means typically
results in hypertrophy, ventricular dysfunction, ventricular remodeling, or frank failure [7]. Thus, sympathetic
activation of the heart is coordinated in part by these two
adrenergic receptors, in which genetic variation of expression or function could act to modify the progression of
heart failure. And indeed, substantial variation in the progression, mortality, and treatment response of heart failure between otherwise similar individuals is well
recognized [8-10].
Previous studies of a common single nucleotide polymorphism C->G in the β1AR gene (ADRB1) at codon 389,
which results in an arginine for glycine substitution
(Arg389Gly), have shown enhanced coupling of the Arg
variant to Gs in recombinant cells [11]. Arg389 is associated with differential exercise capacity in heart failure
patients [12], response to beta-blockers [13,14], hypertension [15], and risk of myocardial infarction [16]. In transgenic mice, the Arg variant has been associated with early
enhanced cardiac function but in older mice a predisposition to heart failure [17].
A common insertion/deletion polymorphism in AfricanAmericans resulting in a consecutive four amino acid loss
(322–325) in the α2CAR gene (ADRA2C) has been found
to reduce receptor function [18], leading to a loss of normal synaptic autoinhibitory feedback and concomitant
enhanced release of norepinephrine [19]. Given the
potential synergistic effects of these polymorphisms in the
ADRB1 and ADRA2C genes, two previous studies have
investigated and identified epistatic interactions affecting
heart failure risk [20] and response to β-blockers in heart
failure patients [21]. In both studies, only two putative
functional polymorphisms (i.e., ADRB1 Arg389Gly and
ADRA2C ins/del 322) were examined. Multiple additional polymorphisms in both of these two intronless
genes have been recently identified and characterized in
whole-gene transfection studies, some of which alter pro-
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tein expression [22,23]. Here we examine whether there is
evidence for more complex intragenic and intergenic epistatic effects on heart failure phenotypes and survival in
these genes utilizing 16 DNA sequence variations in the
ADRA2C and 17 DNA sequence variations in the ADRB1
genes.
Intergenic epistasis, or interaction between two genes,
occurs when the phenotypic effects of a variation in one
gene is affected by a variation in a second gene. This could
result from conformational changes that prevent physical
interaction between the two gene products, or from a
change in the ability of one gene to regulate the expression
of the other or, the pathologic pathway involves both
genes in a manner that their downstream effects converge
to alter critical events. Intragenic epistasis occurs when a
variation in one location of a gene influences the phenotype differently depending on other variations within the
same gene. This type of epistasis is most notable when two
different amino acid substitutions within a gene result in
differentially functioning the resulting protein. However,
it is also seen to have an effect on gene expression and
processing.

Methods
Study Population
The 655 Caucasian heart failure patients were identified
and enrolled in the study at the University of Cincinnati,
Cincinnati, OH, between 1999 and 2004. The study was
restricted to Caucasians because of the significant differences in the allele frequencies between those of Africanand European-descent in these two genes [22,23], and a
smaller number of potential black enrollees. Other enrollment criteria were: age of 18 to 80 years, left ventricular
ejection fraction (LVEF) of less than 40%, and New York
Heart Association heart failure class II-IV. The primary
study endpoint was the combined event of death or cardiac transplantation. Descriptive statistics of this cohort
are given in Table 1. The human study protocols were
approved by the institutional review board of the University of Cincinnati, and subjects provided written informed
consent.
Genotyping
Sequence variants have been previously identified for
ADRA2C [22] and ADRB1 [23] and the nomenclature
used in these papers is retained in the current work to
maintain consistency. Both genes are intronless, and the A
of the initiation codon is denoted as +1, proceeding in the
positive direction 5' -3' through the coding and 3' UTR. In
the 5' -flanking region the most 3' non-coding nucleotide
prior to the ATG is denoted as -1 and the numbering proceeds in the negative direction. The genotyping was performed on the variant sites shown in Table 2. For
orientation purposes +1 of ADRA2C is nucleotide 2638 of
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Table 1: Descriptive statistics for the heart failure cohort

Variable

N

Mean ± SD

Age at onset of heart failure (yrs)
Follow-up time (yrs)
Height (cm)
Weight (kg)
Left Ventricular Ejection Fraction
Left Ventricular Mass indexed to Body Surface Area
Fractional Shortening
Variable

655
655
554
560
415
456
492
N

53.79 ± 12.73
3.16 ± 2.70
172.2 ± 10.06
85.82 ± 20.73
27.72 ± 13.72
189.14 ± 69.04
21.97 ± 11.16
%

Males
Hypertension
Beta Blocker Use
ACE Inhibitor Use
Had Endpoint:

453
310
455
550

69.2
47.9
69.6
84.0

Death
Cardiac Transplant

127
171

19.4
26.1

Dilated Cardiomyopathy
Ischemic Cardiomyopathy
Other

382
259
14

58.3
39.5
2.1

Heart Failure Etiology:

AY605898, and +1 of ADRB1 is nucleotide 36085 of
AL355543. The variants are deposited in the PharmGKB
(ADRA2C) and SeattleSNPs (ADRB1) public databases
(http://www.pharmgkb.org/ and http://pga.gs.washing
ton.edu/, respectively). Genotyping was performed on
genomic DNA derived from blood samples, by sequencing PCR products spanning one or two variant positions,
using an ABI 3730 sequencer. Variants detected by alignment to a reference were verified by visual electropherogram examination.
Statistical Methods
Allele frequencies were estimated using standard gene
counting methods. Hardy-Weinberg disequilibrium was
tested using Weir's method [24]. Linkage disequilibrium
was assessed using the r2 statistic [24]. Cox Proportional
Hazards modeling [25]. was used to test for significant
effects for each polymorphism (separately) and pairwise
epistatic effects after adjustment for age at initial diagnosis, β-blocker usage, hypertension status, and sex. Genotypes for each polymorphism were coded using two
dummy variables where the most frequent genotype was
considered the reference group. Epistasis was assessed by
including interaction terms into the Cox models.

To adjust for multiple testing we used Storey's modification of the false discovery rate (FDR) method of Benjamini and Hochberg [26] that takes into account the
correlation among tests due to linkage disequilibrium. We
used an FDR cutpoint of 0.30. To assess whether the information from the Cox proportional hazards modeling of

genetic effects provides a useful prediction of a new
patient's risk of death or cardiac transplant, we implemented a leave-one-out cross-validation approach [27].
Each individual was sequentially left out and a Cox proportional hazards model for time from study enrollment
to death or cardiac transplant was estimated. Using the
coefficients estimated with the n-1 individuals, a survival
risk was calculated for the individual left out. These risks
were then used as the predictor in a new Cox proportional
hazards model. Because each individual was omitted from
the model used to calculate their survival risk, the performance of a model using these risks as predictors
approximates the predictive ability of the association in
an independent sample drawn from the same population.
In order to assess the overall impact of high-risk two-locus
genotype classes on risk of death or cardiac transplant, a
pooling procedure was performed. If an individual possessed one or more two-locus genotype class that had a
relative risk whose 95% confidence interval was greater
than 1.0, they were assigned the label "has high-risk genotype." All other individuals were assigned the label "does
not have high-risk genotype." Cox proportional hazards
modeling was then performed with this label as the
explanatory variable.

Results
The 655 subject heart failure cohort was 69.2% male, with
47.9% having a history of hypertension, 84.0% receiving
ACE inhibitor therapy and 69.6% receiving β-blocker
therapy (Table 1). Ischemic cardiomyopathies made up
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Table 2: Summary of the SNP frequency distributions

SNP

Genotype (N)

Minor Allele

Minor Allele Freq

H-W P-value

ADRA2C(-2579 T/C)
ADRA2C(-2416 C/G)
ADRA2C(-2357 C/T)
ADRA2C(-2280 G/T)
ADRA2C(-2069 C/T)
ADRA2C(-1926 G/A)
ADRA2C(-1692 T/G)
ADRA2C(-1513 T/G)
ADRA2C(-965 G/C)
ADRA2C(-940 G/A)
ADRA2C(-933 C/A)
ADRA2C(-696 C/G)
ADRA2C(-241 C/G)
ADRA2C(-230 T/C)
ADRA2C(+964 ins/del)
ADRA2C(+1736 G/C)
ADRB1(-4415 T/C)
ADRB1(-4267 ins/del)
ADRB1(-3641 C/T)
ADRB1(-3598 C/T)
ADRB1(-3255 A/C)
ADRB1(-2915 G/A)
ADRB1(-2853 G/A)
ADRB1(-2827 C/A)
ADRB1(-2639 T/C)
ADRB1(-2297 T/G)
ADRB1(-2142 T/C)
ADRB1(-1294 G/A)
ADRB1(-1121 T/C)
ADRB1(-517 T/C)
ADRB1(+145 A/G)
ADRB1(+315 G/T)
ADRB1(+1165 G/C)

568
613
615
612
602
608
624
626
634
634
634
426
644
644
587
651
572
573
593
593
608
643
644
644
637
607
608
579
580
627
584
587
557

C
G
T
T
T
A
G
G
C
A
A
G
G
C
del
C
C
ins
T
T
C
A
A
A
C
G
C
A
C
C
G
T
G

0.013
0.001
0.001
0.002
0.111
0.031
0.069
0.018
0.001
0.136
0.028
0.058
0.001
0.019
0.066
0.235
0.287
0.001
0.146
0.066
0.141
0.001
0.001
0.030
0.433
0.151
0.146
0.003
0.003
0.131
0.146
0.002
0.268

0.000
1.000
1.000
1.000
0.151
1.000
0.066
1.000
1.000
0.615
1.000
0.640
1.000
1.000
0.010
0.387
0.477
1.000
0.073
1.000
0.243
1.000
1.000
0.447
0.568
0.082
0.250
1.000
1.000
0.015
0.018
1.000
0.665

39.5% of the cohort, idiopathic dilated cariomyopaties
comprised 58.3% of the cohort, and the remaining 2.1%
of the cohort had other causes of heart failure, such as primary valvular defects. They had an average age of heart
failure onset of 53.8 years and an average follow-up time
of 3.16 years. Figure 1 shows a Kaplan-Meier curve of time
from heart failure diagnosis to death or cardiac transplant
for this cohort. The minor alleles and the frequencies of
the 16 DNA sequence variations in the ADRA2C and 17
DNA sequence variations in the ADRB1 genes are displayed in Table 2. Eleven of the 16 variants genotyped in
the ADRA2C gene and 11 of the 17 in the ADRB1 gene had
frequencies greater than 1% and are considered polymorphic. Four polymorphisms, ADRA2C(-2579 T/C),
ADRA2C(+964/965 ins/del), ADRB1(-517 T/C), and
ADRB1(+145 A/G), were significantly out of Hardy Weinberg equilibrium (HWE) (P < 0.05). The linkage disequilibrium between polymorphisms is illustrated in Figure 2
and indicates that several polymorphisms within each
gene have significant frequency correlations.

Given the large number of tests for main effects and epistatic effects using these 22 polymorphic loci we used
both the false discovery rate and cross-validation methods
to reduce the probability of false positive results. Table 3
provides a summary of the tests of association between
the polymorphism and age of onset, LVEF, LV mass, and
survival. Overall, only two polymorphisms had significant main effects on the survival distribution and 8 pairs
of polymorphisms had epistatic effects on survival that
were significant (after adjustment by FDR) and cross-validated.
The relative risks (RR) associated with these polymorphisms are listed in Table 4. The two polymorphisms with
single locus effects were ADRA2C(-1692 T/G) and
ADRA2C(+964/965 ins/del). However, both of these polymorphisms were involved in significant epistatic interactions making the interpretation of the relative risks of
their main effects impossible. Even though we equally
tested for interactions within and among the two genes,
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Figure 1
Kaplan-Meier
curve of time from heart failure diagnosis to death or cardiac transplant
Kaplan-Meier curve of time from heart failure diagnosis to death or cardiac transplant.

somewhat surprisingly, we only found evidence of intergenic epistasis. The interaction between ADRA2C(+964/
965 ins/del) and ADRB1(+145 A/G) arises from the
10:AG genotype class having elevated risk of death or
transplant with RR = 5.12 (2.66,9.88). With respect to the
interaction between ADRA2C(-230 T/C) and ADRB1(-517
T/C), the TC:CT genotype class has much higher risk of
death or transplant with RR = 8.31 (3.32, 20.75) compared to the reference genotype class of TT:TT. The interaction between ADRA2C(-230 T/C) and ADRB1(-2297 T/
G) appears to be due to the TC:TG genotype class (RR =
9.23 (3.67,23.16)), and the interaction between
ADRA2C(-1692 T/G) and ADRB1(+145 A/G) is associated
with an increased risk of death or transplant in the TG:AG
genotype class with RR = 4.59 (2.31, 9.12). Likewise, the
interaction between ADRA2C(-1692 T/G) and ADRB1(-

3641 C/T) identifies the TG:CT genotype as the high risk
group with RR = 3.56 (1.80, 7.05). Finally, the ADRA2C(1692 T/G) and ADRB1(-3255 A/C) polymorphism appear
to be interacting and again the TG genotype of the
ADRA2C(-1692 T/G) gene has a significant increase risk in
a particular ADRB1 genotype background – namely, AC
genotype – such that the TG:AC genotype class has a relative risk of 3.02(1.53,5.97).
Given some degree of non-independence among these
epistatic effects, we performed an a posteriori pooling of all
high risk two locus genotype classes with RR's whose 95%
confidence interval exceed 1.0 to attempt to identify the
extent of overlap between the effects from the pairs of loci.
These were compared to all other genotype classes combined, which provides a way to interpret these very spe-
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Figure
A.
Linkage
2 disequilibrium among ADRA2C polymorphisms B. Linkage disequilibrium among ADRB1polymorphisms
A. Linkage disequilibrium among ADRA2C polymorphisms B. Linkage disequilibrium among ADRB1 polymorphisms.
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Table 3: Summary of the significant, false discovery rate adjusted, and cross-validated ADRA2C and ADRB1 polymorphism effects and
interactions on age of onset, LVmass, LVEF, and heart failure survival

ED (N = 655)
Age of Onset

Number of
tests
P < 0.10
FDR (<0.30)
Cross
Validation***
FDR and
Crossvalidation

LVMass Adj*

LVEF Adj**

Survival

SNP Main
Effects

SNP-SNP
Interaction

SNP Main
Effects

SNP_SNP
Interaction

SNP Main
Effects

SNP_SNP
Interaction

SNP Main
Effects

SNP_SNP
Interaction

22

209

22

200

22

204

22

231

2
0
0

24
0
0

1
0
0

8
0
0

2
2
1

16
0
0

4
4
3

50
44
10

0

0

0

0

1

0

2

6

* LVMass was adjusted for age of onset, sex, height, weight, hypertension
** LVEF was adjusted for age of onset, sex
*** For survival analysis, Risk Index was used to cross-validate, P-value for Cox model with Risk Index <0.1 is considered as crossvalidated. For
continuous outcomes, 4-fold CV was used. Press-Rsquared >0.005 (SNP univ model) or Press-Rsquared for full model >0 and Press-Rsquared
Difference between full model and submodel >0.005 (Epistasis) is considered to be crossvalidated for interaction.

cific sets of polymorphisms as if being used clinically.
Here we found that the combined relative risk was 3.35
(1.82, 6.18).

Discussion
In this study, we identified multiple polymorphisms
within the ADRA2C and ADRB1 genes that interact to
increase risk of death or transplant in heart failure
patients. We investigated these genes because numerous
studies in human patient populations [20,12,14], animal
models [17], and in vitro cell systems [18,11,22,23] have
demonstrated their relevance to heart failure phenotypes
or receptor expression/function.
As noted in the Results, four of the polymorphism significantly deviated from Hardy-Weinberg equilibrium. However, a previous study that genotyped the ADRA2C
polymorphisms in a cohort of unaffected individuals did
not show evidence of deviations from HWE [22]. Similarly, genotyping of the ADRB1 polymorphisms in unaffected individuals for the Seattle SNPs database http://
pga.gs.washington.edu/ do not show significant deviations from HWE. The HW deviations we observed could
be due to an underlying association with heart failure [28]
since our sample is exclusively heart failure patients and
these genes have been previously associated with this disease, but random chance and genotyping error cannot be
excluded.
The α2ARs expressed on the presynaptic cardiac sympathetic nerves inhibit the release of norepinephrine when
they are bound by the neurotransmitter [5], and thus pro-

vide a mechanism to regulate release of the neurotransmitter as sympathetic nervous system activity markedly
increases in progressive heart failure. And indeed, in studies of gene-targeted mice where α2ARs have been ablated,
severe cardiomyopathy results due to norepinephrine cardiotoxicity exerted through myocyte β1ARs [5]. The
human ADRA2C ins/del polymorphism previously
denoted Del322-325, and here denoted ADRA2C(+964/
965 ins/del) significantly reduces the function of α2CAR
receptors in transfected cells [18]. While Caucasians have
a very low prevalence of this allele [20] it appears that
other common polymorphisms within this racial group,
in the promoter and 3' UTR region of the gene, affect
receptor expression [22]. Of note, evidence suggests that
there are few "spare receptors" in the complement of
α2CARs expressed in cardiac presynaptic nerves since heterozygous α2CAR knock-out mice (~50% less receptor)
also develop cardiomyopathy under pressure overload
[29]. Thus relatively small changes in expression due to
polymorphisms may have physiologically relevant effects
on the heart during heart failure progression. For the
β1AR, the most frequently studied polymorphic variation
is at nucleotide 1165, where Arg or Gly can be commonly
found at amino acid 389. This lies within a G-protein coupling domain, and in transfected cells the Arg variant
exhibits enhanced coupling to adenylyl cyclase [11]. In
transgenic mice, with matched cardiac expression of the
human β1AR Arg or Gly389 receptors, Arg hearts have
enhanced contractility, but progress to failure by 9months of age, while Gly hearts show less contractile
enhancement and no pathologic effects [17]. The Arg389
phenotype also revealed a gene dose-response, and given
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Table 4: FDR Significant and Cross-Validated Epistatic Effects of ADRA2C and ADRB1 polymorphisms on survival

SNP1

SNP2

Main Effects
ADRA2C(-1692 T/G)

ADRA2C
(+964 ins/del)

Epistatic Effects
ADRA2C
(+964 ins/del)

ADRB1(+145 A/G)

ADRA2C(-230 T/C)

ADRB1(-517 T/C)

ADRA2C(-230 T/C)

ADRB1(-2297 T/G)

ADRA2C(-1692 T/G)

ADRB1(+145 A/G)

ADRA2C(-1692 T/G)

ADRB1(-3641 C/T)

ADRA2C(-1692 T/G) ADRB1(-3255 A/C)

Genotype1 Genotype2

Relative Risk

N

Model P-value

Cross-Validation Pvalue

TT
TG
GG
11

1
1.34(0.91, 1.95)
n/a
1

544
74
6
516

0.029

0.031

0.065

0.018

10
00

0.51(0.07, 3.64)
1.58(1.07, 2.32)*

65
6
<0.001

0.069

<0.001

<0.001

0.001

0.014

0.001

0.097

0.005

<0.001

0.010

<0.001

00

AA

n/a

5

10
10
11
11
11
TC
TC
TT
TT
TT
TC
TC
TT
TT
TT
GG
TG
TG
TG
TT
TT
TT
GG
TG
TG
TT
TT
TT
GG
TG
TG
TT
TT
TT

AA
AG
AA
AG
GG
CT
TT
CC
CT
TT
TG
TT
GG
TG
TT
AA
AA
AG
GG
AA
AG
GG
CC
CC
CT
CC
CT
TT
AA
AA
AC
AA
AC
CC

1.20 (0.74,1.95)
5.12 (2.66, 9.88)*
1
0.86 (0.59, 1.25)
0.70 (0.31, 1.61)
8.31(3.32, 20.75)*
0.46(0.15, 1.42)
0.51(0.21,1.24)
0.88 (0.62,1.26)
1
9.23(3.67,23.16)*
0.61(0.22, 1.64)
0.61(0.27,1.38)
0.99 (0.71,1.36)
1
n/a
0.99 (0.62,1.61)
4.59 (2.31,9.12)*
n/a
1
0.85(0.59, 1.22)
0.61(0.27, 1.38)
n/a
0.95 (0.60, 1.53)
3.56 (1.80,7.05)*
1
0.84 (0.58,1.21)
0.62 (0.27, 1.42)
n/a
1.08 (0.68,1.71)
3.02(1.53,5.97)*
1
0.83(0.58,1.21)
0.73 (0.32,1.66)

39
17
349
108
15
7
16
17
121
455
7
16
18
137
422
5
44
17
2
371
111
17
6
52
18
369
116
17
6
52
19
379
116
16

* RR is significant at α < 0.05

that promoter SNPs of the ADRB1 gene alter expression in
cell-based systems [23], the potential for cardiac relevance
of non-coding β1AR SNPs is apparent.
The previous studies of interactions between one ADRA2C
and one ADRB1 polymorphism illustrate that the physiological effects of variations in these two genes act synergistically to increase risk of heart failure [20] and influences
patient responsiveness to beta-blocker therapy as assessed

by short-term improvements in LVEF [21]. Our study indicates that there may be several other polymorphisms
within these genes that have important physiological and
clinical consequences for heart failure patients. Specifically, the ADRA2C(-1692 T/G) was involved in three epistatic interactions with ADRB1 polymorphisms (+145 A/
G, -3641 C/T, and -3255 A/C) and the ADRA2C(-230 T/C)
polymorphism was involved in two epistatic interactions
with ADRB1 polymorphisms (-2297 T/G and -517 T/C).

Page 8 of 11
(page number not for citation purposes)

BMC Medical Genetics 2008, 9:93

Only one ADRB1 polymorphism (+145 A/G) was
involved in more than one epistatic interaction with the
ADRA2C polymorphisms (-1692 T/G and +964/965 ins/
del). In total, three polymorphisms in the ADRA2C gene
and five polymorphisms in the ADRB1 gene appear to be
implicated in epistatic effects on heart failure survival.
Because of the relatively large number of polymorphisms
investigated in each gene one natural analytical approach
might have been to investigate haplotypes within each
gene and to test for potential interaction between haplotypes in their influence on risk. However, one of the main
drawbacks of such an approach is reducing the haplotype
space to the relevant set with phenotypic effects that could
potentially interact within or across genes. Since we did
not find any evidence of significant intragenic epistasis, it
becomes even more difficult to analyze the diverse set of
haplotypes – many with low frequency – to identify
potentially relevant interactions across genes.
One of the short-comings of genetic association studies is
that they have often failed to replicate and Manly [30] suggests that internal validation, common to good experimental practices, is one way to avoid the publication of
spurious findings. In our study, we used cross-validation
methods to significantly reduce the chance of false positives. Cross-validation methods were developed as a way
to incorporate a measure of predictive accuracy (and correspondingly, a measure of prediction error) for an estimated model based on its performance predicting the
outcome for independent test cases [31]. During the last
decade, cross-validation methods have been used widely
for everything from robust variable selection in gene
expression array studies [32] to reducing false positives in
gene-gene interaction studies [33,34] to evaluating the
predictive accuracy of molecular or genetic classifiers of
disease before clinical implementation [35]. It has
become a standard in the field of metabolomic [36], proteomic [37,38], and transcriptomic [39] studies because
of its ease of execution and its emphasis on prediction in
independent test cases as a method of discriminating
between true associations and false associations.
The epistatic interactions identified here occur between 1692, -230, and the +964/965 polymorphisms of
ADRA2C and -3641, -3255, -2297, -517 and +145 polymorphisms in ADRAB1. We have previously generated
constructs that mimic these polymorphisms and by transient transfection of cells ascertained expression phenotypes (5' and 3' -flanking regions) or signaling phenotypes
(nonsynonymous coding polymorphisms) [11,22,23,18].
All but one of the ADRA2C 5' promoter and 5' UTR polymorphisms found here that interact with ADRAB1 have
been found to influence α2CAR expression in these model
systems. (The ADRA2C(-1692) polymorphism has not

http://www.biomedcentral.com/1471-2350/9/93

been studied in this manner.) And, the +964/965 deletion
polymorphism results in depressed agonist-promoted
function [18]. For the ADRAB1, the aforementioned polymorphisms of the promoter region (except for -1294
which has not been studied) have also been shown to
alter β1AR expression [23]. The nonsynonymous polymorphism at nucleotide position +145 (representing
Gly49) results in a β1AR that undergoes enhanced agonistpromoted downregulation compared to the Ser49 receptor [40], an important phenotype since downregulation is
a protective mechanism in heart failure. Taken together,
then, there is biologic plausibility in the epistatic interactions that were observed. The fact that there is a relatively
large fraction of the patients that do not have these specific combinations, and yet they do display variability in
heart failure progression, indicates additional genetic
(and likely non-genetic) causes for heterogeneity. Within
the axis which we are currently exploring, there are a
number of other genes to be considered. As additional
information from fine mapping and cell-based studies is
obtained, there is the possibility for enhanced predictive
power and an assignment of risk alleles for a greater percentage of heart failure patients. Nevertheless, the current
work shows that epistatic interactions between α2CAR and
β1AR polymorphisms affect heart failure survival, and further confirm the notion that this complex syndrome is
modified by multiple polymorphisms in multiple genes.

Conclusion
Although we did not observe intragenic epistatic interactions between the ADRA2C and ADRB1 genes, we did
observe multiple polymorphisms acting synergistically
between the ADRA2C and ADRB1 genes to increase risk of
death or cardiac transplant in heart failure patients. This
underscores the complexity of the genetic factors that
affect the progression of this syndrome.
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